Novartis' Game Changer: When Failure Turns To Success
Here's what two frequent skeptics have to say about the results of Novartis' new heart failure drug that were presented over the weekend. Stephen Nissen, chair of cardiology at the Cleveland Clinic and probably best known for highlighting safety problems with Merck's painkiller Vioxx, calls it "the first new heart failure drug in decades." Sanjay Kaul of Cedars-Sinai Health System, a stickler for procedure and nuance in the design of clinical trials, says that unless there are problems that only the Food and Drug Administration can uncover, it's "a major win."
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
More News: Cardiology | Clinical Trials | Food and Drug Administration (FDA) | Health | Heart | Heart Failure | Merck | Pharmaceuticals | Vioxx